Related Experiment Video
Updated: Jun 2, 2025
05:42
Author Spotlight: Unlocking the Mysteries of Oral Potential Malignancies
Published on: August 11, 2023
1.0K
Ossifying fibromyxoid tumours: A case series
Javier Pozas1, Khin Thway2, Daniel Lindsay2
1Department of Medical Oncology, The Royal Marsden NHS Foundation Trust, London, UK.
European Journal of Cancer (Oxford, England : 1990)
|January 14, 2025
Summary
Ossifying fibromyxoid tumour (OFMT) is a rare sarcoma. PHF1 rearrangements are common, and while doxorubicin is ineffective, epigenetic therapies show promise.
Area of Science:
- Oncology
- Pathology
- Genetics
Background:
- Ossifying fibromyxoid tumour (OFMT) is a rare mesenchymal soft tissue sarcoma.
- OFMT has uncertain differentiation and variable metastatic potential.
Purpose of the Study:
- To analyze clinical and molecular characteristics of OFMT.
- To evaluate treatment outcomes and identify potential therapeutic targets.
Main Methods:
- Retrospective analysis of 23 OFMT patients (1993-2024).
- Surgical resection of primary tumors.
- Immunohistochemical analysis and next-generation sequencing (NGS).
Main Results:
- Tumors commonly occurred in extremities and trunk.
- PHF1 rearrangements detected in 83% of NGS-tested patients (PHF1::EP400, PHF1::TFE3 fusions).
- Doxorubicin-based chemotherapy showed limited efficacy; one patient responded to gemcitabine and dacarbazine.
Conclusions:
- Multidisciplinary tumor boards are essential for individualized OFMT treatment.
- Epigenetic dysregulation presents a potential therapeutic avenue for OFMT.
- Further research is needed to guide OFMT management.
